Bulk Pharmaceutical API Sources for PENCICLOVIR

Bulk Pharmaceutical API Sources for PENCICLOVIR

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-849-798
Amadis Chemical		A824740
AKos Consulting & Solutions		AKOS007930676
MedChemexpress MCE		HY-17424
AbaChemScene		CS-1355

Bulk Active Pharmaceutical Ingredient (API) Sources for Penciclovir

Last updated: February 20, 2026

Penciclovir is an antiviral nucleoside analogue primarily used for topical treatment of herpes simplex virus (HSV) infections. Its production relies on multiple API suppliers globally, with notable disparities in manufacturing capabilities, regulatory compliance, and market share.

Major API Manufacturers for Penciclovir

Manufacturer	Country	Manufacturing Capacity	Regulatory Approvals	Certification
Jiangsu Hengrui Medicine	China	50 metric tons/year	EMA, U.S. FDA	ISO 9001
Zhengzhou Max Great Pharma	China	20 metric tons/year	CE, GMP compliant	GMP, ISO 9001
Solara Active Pharma Sciences	India	30 metric tons/year	US FDA, EMA	ISO 9001, cGMP
Aurobindo Pharma	India	40 metric tons/year	US FDA	cGMP
Teva Pharmaceutical Industries	Israel / Europe	25 metric tons/year	EMA, U.S. FDA	GMP

API Sourcing Considerations

Regional Distribution

• China: Leading in API manufacturing, especially for APIs like penciclovir, due to high production volume and cost advantages. Several Chinese firms hold large capacity and export globally.
• India: Recognized for high-quality generics, with manufacturers like Aurobindo and Solara meeting international standards and supplying Latin America, Europe, and North America.
• Israel/Europe: Firms such as Teva focus on regulatory compliance and quality assurance, targeting regulatory markets.

Regulatory and Quality Standards

• GMP Compliance: Necessary for API intended for pharmaceutical use. Most top manufacturers adhere to Good Manufacturing Practices.
• Certifications: ISO 9001, cGMP, and sometimes GMP certifications are expected. API suppliers with US FDA or EMA approvals reduce validation efforts for downstream manufacturing.

Supply Chain Risks

• Concentration: The supply chain for penciclovir APIs is concentrated in China and India, exposing manufacturers to geopolitical, regulatory, or trade disruptions.
• Capacity Constraints: Some producers have limited capacity expansions due to regulatory approvals, land, and resource constraints.

Major API Supply Trends

• Vertical Integration: Large pharmaceutical companies often source APIs internally or from trusted suppliers with proven regulatory adherence.
• Generic Market Expansion: Increasing demand for penciclovir generics drives capacity expansion in India and China.
• Pricing Dynamics: Cost-based competition among Chinese and Indian suppliers influences market prices, with Chinese sources typically offering lower prices.

Regulatory Landscape

• US: US FDA inspects and certifies API manufacturers, with most Chinese and Indian providers holding either formal approval or Good Manufacturing Practice (GMP) certificates.
• EU: EMA approval or recognition is necessary for European markets; suppliers with EMA certification are preferred.
• Emerging Markets: Some suppliers export API without formal approval but are used for non-sterile formulations in developing countries.

Market Entry Strategies

• Supplier Qualification: Due diligence on GMP compliance, capacity, past inspection reports, and regulatory approvals.
• Long-term Contracts: Secure supply stability and price competitiveness.
• Regional Partnering: Collaborations with established local distributors in targeted jurisdictions.

Key Takeaways

• Main API producers for penciclovir are located in China and India; these regions dominate manufacturing capacity.
• Quality certifications (GMP, ISO) influence API acceptance by regulated markets.
• Supply chain risks stem from over-reliance on specific regional sources amid geopolitical and pandemic-related disruptions.
• Market expansion relies on capacity growth and regulatory approval of API producers.
• Long-term relationships and rigorous qualification processes matter in securing consistent API supply.

FAQs

1. Which countries are the largest API producers for penciclovir?
China and India dominate as the largest API producers, with capacities exceeding 20 metric tons annually for each.

2. What certifications are critical for API used in regulated markets?
GMP certification and approvals from agencies like the US FDA and EMA are essential for market access and compliance.

3. Are Chinese API suppliers considered reliable for penciclovir?
Many Chinese suppliers are GMP-certified and export globally. Due diligence on regulatory compliance and quality history remains essential.

4. How does supply chain concentration affect penciclovir API sourcing?
Concentration in China and India increases exposure to regional disruptions, emphasizing the need for diversification or dual sourcing strategies.

5. What is the typical capacity range for penciclovir API manufacturers?
Manufacturers usually produce between 20-50 metric tons annually, with capacity expansion dependent on regulatory approvals and demand.

---

References

1. U.S. Food and Drug Administration. (2022). API inspection and certification guidelines.
2. European Medicines Agency. (2022). Regulatory standards for active pharmaceutical ingredients.
3. Global Sources. (2023). API manufacturing capacities and supplier profiles.
4. MarketWatch. (2023). API market trends and regional analysis.
5. IMS Health. (2022). Pharmaceutical industry report on antiviral APIs.

[1] U.S. Food and Drug Administration. (2022). API inspection and certification guidelines.
[2] European Medicines Agency. (2022). Regulatory standards for active pharmaceutical ingredients.
[3] Global Sources. (2023). API manufacturing capacities and supplier profiles.
[4] MarketWatch. (2023). API market trends and regional analysis.
[5] IMS Health. (2022). Pharmaceutical industry report on antiviral APIs.